Cited by 1,076Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Open access

Larochelle, Marc R., Bernson, Dana, Land, Thomas, Stopka, Thomas J., Wang, Na, Xuan, Ziming, Bagley, Sarah M., Liebschutz, Jane M., Walley, Alexander Y.·2018·Annals of Internal Medicine

DOI 10.7326/m17-3107PMC PMC6387681

Open this paper in CoChat — free account

Abstract

Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective: To identify MOUD use after opioid overdose and its association with all-cause and opioid-related mortality. Design: Retrospective cohort study. Setting: 7 individually linked data sets from Massachusetts government agencies. Participants: 17 568 Massachusetts adults without cancer who survived an opioid overdose between 2012 and 2014. Measurements: Three types of MOUD were examined: methadone maintenance treatment (MMT), buprenorphine, and naltrexone. Exposure to MOUD was identified at monthly intervals, and persons were considered exposed through the month after last receipt. A multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality. Results: In the 12 months after a nonfatal overdose, 2040 persons (11%) enrolled in MMT for a median of 5 months (interquartile range, 2 to 9 months), 3022 persons (17%) received buprenorphine for a median of 4 months (interquartile range, 2 to 8 months), and 1099 persons (6%) received naltrexone for a median of 1 month (interquartile range, 1 to 2 months). Among the entire cohort, all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person-years and opioid-related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. Compared with no MOUD, MMT was associated with decreased all-cause mortality (adjusted hazard ratio [AHR], 0.47 [CI, 0.32 to 0.71]) and opioid-related mortality (AHR, 0.41 [CI, 0.24 to 0.70]). Buprenorphine was associated with decreased all-cause mortality (AHR, 0.63 [CI, 0.46 to 0.87]) and opioid-related mortality (AHR, 0.62 [CI, 0.41 to 0.92]). No associations between naltrexone and all-cause mortality (AHR, 1.44 [CI, 0.84 to 2.46]) or opioid-related mortality (AHR, 1.42 [CI, 0.73 to 2.79]) were identified. Limitation: Few events among naltrexone recipients preclude confident conclusions. Conclusion: A minority of opioid overdose survivors received MOUD. Buprenorphine and MMT were associated with reduced all-cause and opioid-related mortality. Primary Funding Source: National Center for Advancing Translational Sciences of the National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7326/m17-3107

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 913
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., Davoli, M., & Breen, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209 · Cited by 536

Flagged first, then by citations

Show all 38 references

4 of the 38 references couldn’t be matched to a known paper.

Sorted by citations

Items 601–700 of 1,000

Post-Overdose Extended-Release Buprenorphine Initiation Facilitated by a Partnership Between Emergency Medical Services and an Outpatient Substance Use Disorder Observation Unit
Taylor, J. L., Gott, J., Weisenthal, K., Colicchio, P., Dyer, S., & Komaromy, M. S. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241249386 · Cited by 5
Post-operative pain control in patients on buprenorphine or methadone for opioid use disorder
Quaye, A., Tsafnat, T., Richard, J. M., Stoddard, H., & Gagnon, D. J. (2024) · Journal of Opioid Management · doi:10.5055/jom.0823 · Cited by 5
Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type
Hayes, C. J., Raciborski, R. A., Nowak, M., Acharya, M., Nunes, E. V., & Winhusen, T. M. (2024) · Addiction · doi:10.1111/add.16659 · Cited by 5
Medicaid managed care restrictions on medications for the treatment of opioid use disorder
Stewart, M. T., Andrews, C. M., Feltus, S. R., Hodgkin, D., Horgan, C. M., Parks, C. L., & Nong, T. (2024) · Health Services Research · doi:10.1111/1475-6773.14394 · Cited by 5
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort
Reif, S., Stewart, M. T., Daily, S. M., Brolin, M. F., Lee, M. T., Panas, L., Ritter, G. A., Shields, M. C., Mazel, S. B., & Wicks, J. J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209544 · Cited by 5
The first five years of implementing Missouri's medication first approach to opioid use disorder treatment: Plateaus, regressions, and underbellies of progress
Winograd, R., Park, B., Coffey, B., Ghonasgi, R., Blanchard, B., Thater, P., & Brown, K. C. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209622 · Cited by 4
Pharmacy harm reduction practices to help reduce opioid overdoses, Arizona 2023
Meyerson, B. E., Richter, S., Gordon, R., Chang, E. P. Y., Vadiei, N., Eldridge, L. A., Higbie, E. O., Pal, A. A., Seckar-Martinez, A., Newgass, K., et al. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102348 · Cited by 5
Adaptive decision support for addiction treatment to implement initiation of buprenorphine for opioid use disorder in the emergency department: protocol for the ADAPT Multiphase Optimization Strategy trial
Iscoe, M. S., Hooper, C., Levy, D. R., Buchanan, L., Dziura, J. D., Meeker, D., Taylor, R. A., D’Onofrio, G., Oladele, C., Sarpong, D. F., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-098072 · Cited by 4
Methadone Induction for a Patient With Precipitated Withdrawal in the Emergency Department: A Case Report
Church, B. J., Clark, R., Mohn, W., Potee, R. A., Friedmann, P. D., & Soares, W. E. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001109 · Cited by 5
Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder
Clingan, S. E., Cousins, S. J., Lin, C., Nguyen, T. E., Hser, Y., & Mooney, L. J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2169342 · Cited by 5
Identifying Barriers to OUD Treatment Linkage From the Emergency Department to the Community
Calcaterra, S. L., Martín, M., & Englander, H. L. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.12683 · Cited by 5
Applied machine learning analysis: Factors correlated with injection drug use and post-prison medication for opioid use disorder treatment engagement
Victor, G. A., Roddy, A. L., Lenz, D., Willis, T. M., & Kubiak, S. P. (2023) · Journal of Offender Rehabilitation · doi:10.1080/10509674.2023.2213693 · Cited by 5
Viewing Then Doing?: Problem-Solving Court Coordinators’ Perceptions of Medications for Opioid Use Disorders from a Nationally Representative Survey in the United States
Smith, L. R., Faragó, F., Blue, T. R., Witte, J. C., Gordon, M., & Taxman, F. S. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2247076 · Cited by 5
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
Bahji, A., Bastien, G., Bach, P., Choi, J., Foll, B. L., Lim, R., Jutras‐Aswad, D., & Socias, M. E. (2023) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231194385 · Cited by 4
“I want to stay here”: Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care
Martinez, N. G., Truong, A. Q., Nordeck, C. D., Agus, D., Genberg, B. L., & Buresh, M. E. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111130 · Cited by 5
Cancer Pain Management in Patients with Opioid Use Disorder
Nickels, K., Kullgren, J. G., Mitchell, M. T., Carter, M., Kasberg, B., Holbein, M., Gamble, A., Thompson, B., Koolwal, A., & Ho, J. J. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00577-9 · Cited by 5
Long-term use of prescription opioids for non-cancer pain and mortality: a population-based, propensity-weighted cohort study
Hurtado, I., Robles, C., García‐Sempere, A., Llopis-Cardona, F., Sánchez‐Sáez, F., Rodríguez-Bernal, C. L., Peiró, S., & Sanfélix‐Gimeno, G. (2024) · Public Health · doi:10.1016/j.puhe.2024.04.009 · Cited by 5
Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts
Chatterjee, A., Stewart, E. A., Assoumou, S. A., Chrysanthopoulou, S. A., Zwick, H. C., Harris, R. A., O’Dea, R., Schackman, B. R., White, L. F., & Linas, B. P. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.37233 · Cited by 5
Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages
Gilbert, M. K., Daughton, A. R., Chilcoat, H. D., Laffont, C. M., Strafford, S., & DeVeaugh‐Geiss, A. (2025) · Journal of Medical Internet Research · doi:10.2196/71245 · Cited by 5
Patient Characteristics Affect Discharge Status for Opioid-related Infective Endocarditis
Schuller, K. A., Franz, B. A., & Cronin, C. E. (2019) · Medical Care · doi:10.1097/mlr.0000000000001233 · Cited by 5
Understanding ED Buprenorphine Initiation for Opioid Use Disorder: A Guide for Emergency Nurses
Strout, T. D., Baumann, M. R., & Wendell, L. (2020) · Journal of Emergency Nursing · doi:10.1016/j.jen.2020.10.001 · Cited by 5
Technology-assisted opioid education for out-of-treatment adults with opioid use disorder.
Toegel, F., Novak, M. D., Rodewald, A. M., Leoutsakos, J., Silverman, K., & Holtyn, A. F. (2021) · Psychology of Addictive Behaviors · doi:10.1037/adb0000769 · Cited by 5
Predicting the impact of placing an overdose prevention site in Philadelphia: a mathematical modeling approach
Wares, J. R., Dong, J., Gevertz, J. L., Radunskaya, A., Viner, K. M., Wiebe, D. J., & Solomon, S. R. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00559-4 · Cited by 7
Identifying barriers to emergency department-initiated buprenorphine: A spatial analysis of treatment facility access in Michigan
Dora‐Laskey, A., King, A. M., & Sadler, R. C. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.11.014 · Cited by 5
Disparities in naloxone prescriptions in a University Hospital during the COVID-19 pandemic
Chieh, K. Y., Patel, I., Walter, L. A., & Li, L. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00667-9 · Cited by 5
Severe, Nondelirium Agitation as an Underreported Characteristic of Precipitated Fentanyl Withdrawal: A Case Report
Terasaki, D., & Brady, J. L. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001017 · Cited by 5
Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment
Gray, J. R., Kehoe, L. G., Peckham, A. M., & Wakeman, S. E. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001067 · Cited by 5
Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
Raman, S. R., Ford, C. B., Hammill, B. G., Clark, A. G., Clifton, D., & Jackson, G. L. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00396-9 · Cited by 5
Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment
MacLean, R. R., Ankawi, B., Driscoll, M., Gordon, M. A., Frankforter, T. L., Nich, C., Szollosy, S. K., Loya, J. M., Brito, L., Ribeiro, M. I. P., et al. (2024) · JMIR Research Protocols · doi:10.2196/54342 · Cited by 6
Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios
Tatara, E. R., Lin, Q., Ozik, J., Kolak, M., Collier, N. T., Halpern, D., Anselin, L., Dahari, H., Boodram, B., & Schneider, J. A. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012307 · Cited by 5
Role of an Accurate Treatment Locator and Cash-Only Practices in Access to Buprenorphine for Opioid Use Disorders
Lagisetty, P., & Bohnert, A. S. B. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1429 · Cited by 5
Employment Trajectories among Individuals with Opioid Use Disorder: Can Evidence-Based Treatment Improve Outcomes?
Burke, M. A., Sullivan, R., Carman, K. G., Wen, H., Wharam, J. F., & Yu, H. (2022) · Working paper series · doi:10.29412/res.wp.2022.25 · Cited by 5
Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures
Dai, Z., Abate, M. A., Winstanley, E. L., Kraner, J. C., Lundstrom, E. W., Mock, A. R., & Smith, G. S. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209252 · Cited by 5
Evidence-based treatment for opioid use disorder is widely unavailable and often discouraged by providers of residential substance use services in North Carolina
Carroll, J. J., Dasgupta, N., Ostrach, B. M. M., El‐Sabawi, T., Dixon, S. K., Morrissey, B., & Saucier, R. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209474 · Cited by 4
Rates of buprenorphine prescribing and racial disparities among patients with opioid overdose
Chieh, K. Y., Walter, L. A., Cropsey, K. L., & Li, L. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100298 · Cited by 4
Improving Access To Substance Use Disorder Care In Nursing Facilities
Kelly, L. A., Accetta, R. C., Conroy, M. B., & Myrka, A. (2025) · Health Affairs · doi:10.1377/hlthaff.2025.00337 · Cited by 4
Impact of Substance Use Navigators on Initiation of Treatment for Substance Use Disorders and 30-Day Unplanned Readmission
Campbell, A., Rosen, A. D., SHOPTAW, S. J., Herring, A. A., Jay, D., Moulin, A. K., LaMers, J., Samuels, E. A., & Gietzen, L. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09902-y · Cited by 4
Polydrug overdose mortality caused by synthetic opioids and stimulants: current sex- and age-specific trajectories in United States national data for 2018–2024
Butelman, E. R., Huang, Y., Shastry, S., Manini, A. F., Goldstein, R. Z., & Nelly Alia-klein, A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02284-z · Cited by 4
Opioid use disorder and concurrent benzodiazepine use: clinical risks and management strategies
Fakhri, A., Ritvo, A. D., Casarella, J., & Tang, Y. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2593244 · Cited by 4
Mobile addiction treatment units: a narrative review
Barrera, I., Wang, G., Rajakumar, B., Muthupalaniappan, S., Cronin, A. E., & Chatterjee, A. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00619-1 · Cited by 4
Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a Multisite, Randomized Controlled Trial Conducted Within the National Institute on Drug Abuse Clinical Trials Network
Papa, C. E., McClure, E. A., McCauley, J. L., Haynes, L. F., Matheson, T., Jones, R. N., Jennings, L. K., Lawdahl, T., Ward, R. C., Brady, K. T., et al. (2024) · JMIR Research Protocols · doi:10.2196/60277 · Cited by 4
Brief Report on Outpatient Treatment of Adolescent Opioid Use Disorder
Kaliamurthy, S., Straton, E., Kumar, P., & Carleen, A. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001391 · Cited by 4
Precipitated Withdrawal Induced by Prehospital Naloxone Administration
Vandergrift, L. A., Rice, A. D., Primeau, K., Gaither, J. B., Munn, R. D., Hannan, P. L., Knotts, M., Hollen, A., Stevens, B., Lara, J., et al. (2025) · Prehospital Emergency Care · doi:10.1080/10903127.2024.2449505 · Cited by 4
Trends in Extended-Release and Non–Extended-Release Buprenorphine Dispensing
Stopka, T. J., Dalvi, N., Young, L. D., Shrestha, S., Valerio, D. D., & Walley, A. Y. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.3158 · Cited by 4
Self-citation
Building connection: overdose survivors’ and professional service providers’ perspectives on immediate post-overdose care
Paradise, R. K., Kimmel, S. D., Nurani, A., Desmarais, J., O’Malley, S., Walley, A. Y., Hoyos-Céspedes, A., Clarke, J., Taylor, S., Dooley, D. P., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104948 · Cited by 4
Self-citation
Medicaid: Increased Patient Access To MOUD In Residential Treatment Associated With Facility Openings And Closures, 2012–22
Beetham, T., Newton, H., Ndumele, C. D., Fiellin, D. A., & Busch, S. H. (2025) · Health Affairs · doi:10.1377/hlthaff.2025.00348 · Cited by 4
Offering Emergency Buprenorphine Without a Prescription
Roy, P. J., & Stein, M. D. (2019) · JAMA · doi:10.1001/jama.2019.8309 · Cited by 4
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs
Poorman, E. A., Glick, S. N., Hiser, J. K. D., Bhatraju, E. P., & Tsui, J. I. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108375 · Cited by 4
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity
Shastry, S., Nobel, I., Allen, L. R., Richardson, L. D., Vidal, K., & Manini, A. F. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.10.012 · Cited by 4
Experiences Using a Multidisciplinary Model for Treating Injection Drug Use Associated Infections: A Qualitative Study
Nolan, N. S., Gleason, E. G., Marks, L. R., Habrock-Bach, T., Liang, S. Y., & Durkin, M. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.924672 · Cited by 4
Perceptions and Experiences With Evidence-based Treatments Among People Who Use Opioids
Carlberg-Racich, S., Sherrod, D., Swope, K., Brown, D. A., Afshar, M., & Salisbury‐Afshar, E. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001064 · Cited by 4
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder
Hefner, K. R., Choo, T.-H. J., Shmueli‐Blumberg, D., Pavlicová, M., King, J., Fishman, M. J., Shulman, M., Campbell, A. N. C., Greiner, M. G., Scodes, J. M., et al. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100100 · Cited by 4
Total cost of care associated with opioid use disorder treatment
Toseef, M. U., Durfee, J., Podewils, L. J., Blum, J., McEwen, D., Hanratty, R. L., & Everhart, R. M. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107345 · Cited by 4
Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes
Young, G. J., Hasan, M. M., Young, L. D., & Noor‐E‐Alam, M. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2177111 · Cited by 4
Use of Big Data and Ethical Issues for Populations With Substance Use Disorder
Evans, E., & Geissler, K. H. (2023) · Value in Health · doi:10.1016/j.jval.2023.02.019 · Cited by 4
Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder
Serdarevic, M., Cvitanovich, M. J., MacDonald, B. R., d’Etienne, J. P., DeMoss, D. S., & Ojha, R. P. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2023.06.014 · Cited by 4
Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area
Filiatreau, L. M., Szlyk, H. S., Kasson, E. M., Dickson, M. F., Banks, D. E., Winograd, R., Marotta, P. L., & Cavazos‐Rehg, P. A. (2024) · Journal of Drug Issues · doi:10.1177/00220426241229972 · Cited by 4
Substance Use Disorder Treatment Carve Outs in Medicaid Managed Care
Silverman, A., Westlake, M. A., Hinds, O. M., Harris, S. J., Abraham, A. J., Grogan, C. M., & Andrews, C. M. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209357 · Cited by 4
Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
Hammerslag, L. R., Talbert, J., Slavova, S. S., Lei, F., Freeman, P. R., Marks, K. R., Fanucchi, L. C., WALSH, S. L., & Lofwall, M. R. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209391 · Cited by 4
Drug Overdose Death Following Substance Use Disorder Treatment Termination in New York City: A Retrospective Longitudinal Cohort Study
Jordan, A. E., Jette, G., Graham, J. K., Burke, C., & Cunningham, C. O. (2024) · Journal of Urban Health · doi:10.1007/s11524-024-00893-5 · Cited by 4
Spatiotemporal forecasting of opioid-related fatal overdoses: towards best practices for modeling and evaluation
Heuton, K., Kapoor, J., Shrestha, S., Stopka, T. J., & Hughes, M. C. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae343 · Cited by 4
Self-citation
How emergency departments are responding to the opioid crisis: Results from a statewide survey in Kentucky
Sugarman, O. K., Harris, S. J., Byrne, L., Flanagan, V., Gattine, S., Desai, I., Heidari, O., Gibbons, J. B., Whaley, S., Lucas, D., et al. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00512-3 · Cited by 4
Dynamics of prescribing and accessing medications for opioid use disorder: a community-based systems analysis
Herman, T., Hasgül, Z., Lim, T. Y., Jalali, M. S., & Stringfellow, E. J. (2024) · Addiction Research & Theory · doi:10.1080/16066359.2024.2420087 · Cited by 4
Insurmountable antagonism of human mu opioid receptors by buprenorphine is due to hemi-equilibrium
Wedemeyer, M. J., Chavera, T. S., Berg, K. A., & Clarke, W. P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177192 · Cited by 4
Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl
Romano, I. G., Johnson‐Weaver, B. T., Core, S. B., Jamus, A. N., Brackeen, M. F., Blough, B. E., Dey, S., Huang, Y., Staats, H. F., Wetsel, W. C., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01105-0 · Cited by 4
Evaluation of Substance Abuse Cases Admitted in ICU of Poison Control Center- Ain Shams University Hospitals by Certain Clinical Scoring Systems
Eldin, R. E., Othman, H., & Eldin, H. S. (2021) · Ain Shams Journal of Forensic Medicine and Clinical Toxicology · doi:10.21608/ajfm.2021.138851 · Cited by 4
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder
Dowd, W. N., Barch, D. H., Seibert, J., & Mark, T. L. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108824 · Cited by 4
Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder
Lin, L. A., Powell, V. D., Macleod, C., Bohnert, A. S. B., & Lagisetty, P. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108827 · Cited by 4
Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder
Saunders, E. C. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220687 · Cited by 4
Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis
Howell, B. A., Black, A. C., Grau, L. E., Lin, H., Greene, C., Lee, H., Heimer, R., Hawk, K. F., D’Onofrio, G., Fiellin, D. A., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109788 · Cited by 4
Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009–2018
Schuler, M. S., Dick, A. W., Gordon, A. J., Saloner, B. K., Kerber, R., & Stein, B. D. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111290 · Cited by 4
Uso problemático de los analgésicos opioides de prescripción: clasificación y tratamientos eficaces
Ruiz, A. I. H. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.10.008 · Cited by 4
Correlates of death during outpatient treatment for opioid use disorder: A national study
Goldman, J. A., Samuels, E. A., Rich, J. D., & Marshall, B. D. L. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.01.003 · Cited by 4
Opioid, Cocaine and Methamphetamine Overdose Crisis and Deaths in 2021
Gold, M. S. (2021) · Journal of Addiction Science · doi:10.17756/jas.2021-050 · Cited by 4
Facing Addiction
Wakeman, S. E. (2019) · Psychiatric Annals · doi:10.3928/00485713-20190108-01 · Cited by 4
State Approaches to Addressing the Overdose Epidemic: Public Health Focus Needed
Davis, C. S., Green, T. C., LaSalle, L., & Beletsky, L. A. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519857315 · Cited by 4
Time to Change the Way We Approach Opioid Use Disorder: A Challenge to the Status Quo
Hawk, K. F., & D’Onofrio, G. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2722 · Cited by 4
Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs
Barocas, J. A., & Saitz, R. (2018) · Annals of Internal Medicine · doi:10.7326/m18-3293 · Cited by 4
Who Gets Medication-assisted Treatment for Opioid Use Disorder, and Does It Reduce Overdose Risk? Evidence from the Rhode Island All-payer Claims Database
Burke, M. A., Sullivan, R., Carman, K. G., Wen, H., Wharam, J. F., & Yu, H. (2021) · Working paper series · doi:10.29412/res.wp.2021.03 · Cited by 4
Approaches, Barriers, and Facilitators in Statewide Initiative to Combat Opioid Overdose: A Narrative Review of Ohio’s Experiences During the HEALing Communities Study
McMullan, J. T., Mueller, W., Brown, J. L., Ewing, I., Lyons, M. S., Sprunger, J., Winhusen, T. M., & Collins, T. (2025) · Prehospital Emergency Care · doi:10.1080/10903127.2025.2451214 · Cited by 3
Overdose-Related Cardiac Arrest in the Era of the Opioid Epidemic
Buckley, R. H., Yang, D. H., D’Onofrio, G., & Perman, S. M. (2025) · Critical Care Clinics · doi:10.1016/j.ccc.2025.08.008 · Cited by 3
Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
Roy, P. J., Colvin, R., Nickel, K. B., Ross, R. K., Durkin, M. J., Suda, K. J., Atkinson, A., & Butler, A. M. (2025) · Addiction · doi:10.1111/add.70288 · Cited by 3
Understanding barriers and facilitators to women’s recovery from opioid use disorder: a focus group study
Ward‐Peterson, M., Mommaerts, K., Jafry, A., Greenamyre, E., Hughson, W., Landry, R., Sasser, C., Soria, M., Mortensen, E. S., & Wagner, E. F. (2026) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2026.2618008 · Cited by 3
Methadone Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder
Meredith, R. R., Garneau, W. M., Feder, K. A., & Buresh, M. E. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.3439 · Cited by 3
Policies regarding Use of Medications for Opioid Use Disorder in Professional Recovery Programs: A Scoping Review
White, K. M., Hill, L. G., Perez, J. C., Torrez, S. B., Zagorski, C. M., & Loera, L. J. (2022) · Substance Abuse · doi:10.1080/08897077.2021.2010161 · Cited by 3
Emergency Department–Initiated Interventions for Illicit Drug Overdose: An Integrative Review of Best Practices
Mechling, B., Ahern, N. R., Palumbo, R., Bebawy, A., & Zumpe, R. L. (2022) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20221123-01 · Cited by 3
Concordance of opioid exposure in all‐payer claims databases with prescription drug monitoring program database using Arkansas as a case example
Mahashabde, R. V., Shrikhande, M. A., Han, X., Martin, B. C., ElHassan, N. O., & Hayes, C. J. (2022) · Health Services Research · doi:10.1111/1475-6773.14117 · Cited by 3
Implementation of medication for opioid use disorder treatment in Indian health clinics in California: A qualitative evaluation
Soto, C., Miller, K. A., Moerner, L., Nguyen, V., & Ramos, G. G. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209115 · Cited by 3
Demographics and Clinical Characteristics of Patients With Opioid Use Disorder and Offered Medication-Assisted Treatment in the Emergency Department
Fu, W. W., Adzhiashvili, V., & Majlesi, N. (2023) · Cureus · doi:10.7759/cureus.41464 · Cited by 3
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
Pytell, J. D., Fojo, A. T., Keruly, J. C., Snow, L. N., Falade-Nwulia, O. O., Moore, R. D., Chander, G., & Lesko, C. R. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00408-8 · Cited by 3
“SafetyNet”: Evaluation of a Recovery Coach and Paramedic Intervention Following Naloxone Resuscitation From an Opioid Overdose
Joseph, D., Brokowski, C., D’Onofrio, G., Bogucki, S., McGovern, J., Allen, R., Dziura, J., Cone, D. C., & Pantalon, M. (2024) · Substance use & addiction journal · doi:10.1177/29767342241266412 · Cited by 3
Factors affecting problem-solving court team decisions about medications for opioid use disorder
Andraka‐Christou, B., Viglione, J., Ahmed, F. Z., del Pozo, B., Atkins, D. N., Clark, M. H., Totaram, R., & Pivovarova, E. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209525 · Cited by 3
Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting
Burke, A., Vadiei, N., & Mollon, L. E. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100292 · Cited by 3
Physical Accessibility Barriers to Medications for Opioid Use Disorder Treatment: A Qualitative Study of Perspectives from Women with Opioid Use Disorder and Health and Criminal Legal Professionals
Skogseth, E. M., Brant, K., Latkin, C. A., & Jones, A. A. (2025) · Contemporary Drug Problems · doi:10.1177/00914509241309110 · Cited by 3
Sex and race-ethnicity influences on opioid overdose deaths among veterans diagnosed with opioid use disorder between 2016 and 2021
Mandavia, A. D., Fonda, J. R., Banducci, A. N., Ameral, V., Sistad, R. E., Loeffel, L. B., Roth, C. E., Simpson, T. L., Stein, M. D., Marx, B. P., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112764 · Cited by 3
Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial
Brown, J. L., Larochelle, M. R., Fanucchi, L. C., Calvert, D., Campbell, A. N. C., Chandler, R. K., Feaster, D. J., Glasgow, L., Gibson, E. B., Holloway, J., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112785 · Cited by 3
Self-citation
Treatment Initiation and Outcomes Associated With Receipt of Emergency Department-Based Peer Support Following Opioid Overdose
Treitler, P. C., Lloyd, K., Cantor, J. C., Chakravarty, S., Crystal, S., Kline, A., Morton, C. M., Powell, K. G., Borys, S. V., & Cooperman, N. A. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.06.616 · Cited by 3
Medicaid prescription cap policies and exemptions for medications for opioid use disorder: A process and content analysis
Hughto, J. M. W., Vento, S. A., Pletta, D. R., Noh, M., Shireman, T. I., Santostefano, C. M., Hughes, L. D., Peterson, L., Seymour, E., Stettenbauer, E. G., et al. (2025) · Health Affairs Scholar · doi:10.1093/haschl/qxaf203 · Cited by 3
Association of Adverse Events in Opioid Addiction Treatment With Quality Measure for Continuity of Pharmacotherapy
Liu, Y., Becker, A., & Mattke, S. (2022) · Journal for Healthcare Quality · doi:10.1097/jhq.0000000000000338 · Cited by 3
The United States must improve its data infrastructure to ensure high-quality mental health care
Mark, T. L. (2023) · Frontiers in Health Services · doi:10.3389/frhs.2023.1059049 · Cited by 3

Authors: Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y.
Affiliations: Boston University (US)
Massachusetts Department of Public Health (US)
Tufts University (US)
ORCID: Larochelle, Marc R.
Bernson, Dana
Stopka, Thomas J.
Wang, Na
Xuan, Ziming
Bagley, Sarah M.
Liebschutz, Jane M.
Walley, Alexander Y.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2018-08-07
Volume: 169
Issue: 3
Pages: 137-145
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/m17-3107
PMC: PMC6387681
OpenAlex: W2808907017
Cited by: 1,076
References: 38
Citations by year: 2026: 99 · 2025: 140 · 2024: 161 · 2023: 133 · 2022: 134 · 2021: 157 · 2020: 117 · 2019: 113 · 2018: 21
FWCI: 97.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001430)
National Institute on Drug Abuse (K23DA042168)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: opioid use disorder, medication-assisted treatment, methadone maintenance treatment, buprenorphine, naltrexone, opioid-related deaths, all-cause mortality, opioid overdose prevention
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Massachusetts, Methadone, Middle Aged, Mortality, Naltrexone, Opioid-Related Disorders, Retrospective Studies, Proportional Hazards Models, Young Adult, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks